comparemela.com
  1. Home
  2. Live Updates
  3. Enrique Conterno - Breaking News

Latest Breaking News On - Enrique conterno - Page 5 : comparemela.com

FibroGen to Participate at William Blair Biotech Focus Conference 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

South koreaMichael tungEnrique conternoMeichiel keenanFibrogen incCorporate communicationsChief executive officerWilliam blair biotech focus conferenceFibrogen investorsInvestor relationsGlobe newswire

FibroGen to Present at Jefferies Healthcare Conference

FibroGen to Present at Jefferies Healthcare Conference
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Michael tungEnrique conternoMeichiel keenanFibrogen incCorporate communicationsChief executive officerJefferies healthcare conferenceFibrogen investors

FibroGen, Inc s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript

FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q1 2022 Earnings Conference Call May 09, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno –.

United statesUnited kingdomRussian federationMichael tungJohn hunterDjuan grahamAndy hsiehYaron werberJason gerberryAnnabel samimyMike yeeChris chungMichael yeeEnrique conternoMark eisnerWilliam blair

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,.

United kingdomUnited statesSouth africaOrenburgskaya oblastNew zealandArkhangel skaya oblastSouth koreaSteven bennerIndianj anaesthKenji yasukawaEnrique conternoMark eisnerJonathan barrattFibrogen incNational institute of diabetesUniversity of leicester

Astellas Receives European Commission Approval for

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia.

United kingdomUnited statesSouth africaNew zealandOrenburgskaya oblastSouth koreaMichael tungSteven bennerAnna ottenKenji yasukawaEnrique conternoMark eisnerJonathan barrattFibrogen incUniversity of leicesterEuropean commission

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.